The US Supreme Court has vacated an appeals court judgment that invalidated a patent covering Teva’s blockbuster drug Copaxone (glatiramer acetate).
Japanese pharmaceutical company Shionogi has sued Aurobindo Pharma in an attempt to stop the Indian generic drug maker from marketing a version of its antibiotic drug Doribax (doripenem) in the US.
Pharmaceutical companies Teva and Mylan have each been granted permission to market a generic version of Novartis’s blood pressure treatment Diovan (valsartan) in the US.
Pharmaceutical companies will suffer an estimated $65 billion drop in sales over the next five years due to the expiry of patents protecting several leading drugs, according to a UK research and consulting firm.
Pharmaceutical company Supernus and its subsidiary Galderma have had their Oracea (doxycycline) acne treatment drug protected from a generic challenge, in a decision dubbed the “first of its kind”.
Pharmaceutical company Merck has said it will press on with an $8.4 billion buyout of Cubist Pharmaceuticals despite a court ruling that could pave the way for a generic version of a lucrative Cubist drug.
A US court has spared drug companies AstraZeneca and Ranbaxy Laboratories a potentially hefty fine after ruling that a ‘pay-for-delay’ deal between them did not violate antitrust grounds.
Indian drug maker Ranbaxy Laboratories has sued the US Food and Drug Administration and claimed it wrongfully revoked a previous approval for two new drugs.
A case that was expected to act as a benchmark for future patent cases in Canada has been settled a day before the country’s Supreme Court was due to hear arguments.
Canada’s highest court is set to hear a hotly anticipated dispute pitting generic company Apotex against drug companies Sanofi and Bristol-Myers Squibb (BMS).